Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons

AIDS

Volumn 25, Issue 10, 2011, Pages 1289-1298

  Choi, Andy I ^a,b   Vittinghoff, Eric ^b   Deeks, Steven G ^c   Weekley, Cristin C ^a   Li, Yongmei ^a   Shlipak, Michael G ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of California   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

antiretroviral therapy; cardiovascular disease; heart failure; HIV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; TENOFOVIR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HEART FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATION; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STANDARDIZATION; VETERAN;

ADENINE; ANTI-RETROVIRAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RISK FACTORS; UNITED STATES; VETERANS; VIRAL LOAD;

EID: 79958834478     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328347fa16     Document Type: Article

References (54)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95. (Pubitemid 351640011)
3. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
4. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. In Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services; 2008. pp. 1-128.
5. Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS 2007; 21:2093-2100. (Pubitemid 47462159)
6. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antire-troviral therapy: New York City. Ann Intern Med 2006; 145: 397-406. (Pubitemid 46768570)
7. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118:198-210.
8. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651-658.
9. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28.
10. Cutrell A, Brothers C, Yeo J, Hernandez J, Lapierre D. Abacavir and the potential risk of myocardial infarction. Lancet 2008; 371:1413.
11. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
12. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. (Pubitemid 46658704)
13. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201:318-330.
14. Post FA, Campbell LJ. Abacavir and increased risk of myocar-dial infarction. Lancet 2008; 372:803; author reply 804-805.
15. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53:62-69.
16. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
17. Aberg JA, Ribaudo H. Cardiac risk: not so simple. J Infect Dis 2010; 201:315-317.
18. Backus LI, Gavrilov S, Loomis TP, Halloran JP, Phillips BR, Belperio PS, et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16:775-783.
19. Maynard C, Chapko MK. Data resources in the Department of Veterans Affairs. Diabetes Care 2004; 27 (Suppl 2):B22-B26. (Pubitemid 38569260)
20. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002; 12:462-468.
21. United States Renal Data System. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
22. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
23. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121:651-658.
24. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis 2007; 45:1633-1639. (Pubitemid 351411850)
25. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006; 44:S13-S24. (Pubitemid 44284253)
26. Office USGA. Veterans healthcare: use of VA services by Medicare-eligible veterans. In GAO Report. Washington, D.C.; 1994.
27. Shen Y, Hendricks A, Zhang S, Kazis LE. VHA enrollees' healthcare coverage and use of care. Med Care Res Rev 2003; 60:253-267. (Pubitemid 36605436)
28. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patient- and provider-reported adherence: toward a clinically useful approach to measuring anti-retroviral adherence. J Clin Epidemiol 2001; 54 (Suppl 1):S91-S98. (Pubitemid 34013694)
29. Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000; 11:155A.
30. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 2005; 19 (Suppl 3):S99-S105. (Pubitemid 41682176)
31. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimatesof diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 2004; 27 (Suppl 2):B10-B21. (Pubitemid 38569259)
32. Selby JV, Peng T, Karter AJ, Alexander M, Sidney S, Lian J, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care 2004; 10:163-170. (Pubitemid 38332390)
33. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
34. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir-emtri-citabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-1601.
35. Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis 23:9-14.
36. Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 24:F1-F9.
37. Marchetti G, Casana M, Tincati C, Bellistri GM, Monforte A. Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role? Clin Infect Dis 2008; 47:1495-1496.
38. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-2027.
39. Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med 2009; 10: 627-633.
40. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108. (Pubitemid 351263473)
41. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198. (Pubitemid 40490248)
42. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008; 22: 2155-2163.
43. Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, Chmiel J, et al. Renal function in tenofovir-exposed and teno-fovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic Ill) 2007; 6:178-187.
44. Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, et al. Incidence of and risk factors for tenofovir-induced ne-phrotoxicity: a retrospective cohort study. HIV Med 2005; 6:284-290. (Pubitemid 41025294)
45. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007; 21:1431-1439. (Pubitemid 46988003)
46. Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008; 47:1449-1457.
47. Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A, et al. Racial differences in incident heart failure among young adults. N Engl J Med 2009; 360:1179-1190.
48. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147.
49. Isakova T, Gutierrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009; 76:705-716.
50. Marcussen N. Atubular glomeruli and the structural basis for chronic renal failure. Lab Invest 1992; 66:265-284.
51. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112:2627-2633. (Pubitemid 41532599)
52. Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009; 120:1784-1792.
53. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16:520-528. (Pubitemid 41725150)
54. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20:397-404.